NSABP B-31

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的主要目的是：1)比较四个周期的AC和四个周期的紫杉醇，以及相同的化疗方案加赫赛汀对HER2蛋白过度表达的可手术的、组织学阳性的乳腺癌患者的心脏毒性；以及2)确定在该患者群体中，四个周期的AC然后四个周期的紫杉醇和每周一年的赫赛汀是否比四个周期的AC然后四个周期的紫杉醇更有效地延长生存期

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of the study are 1) to compare the cardiotoxicity of four cycles of AC followed by four cycles of Taxol, with that of the same chemotherapy regimen plus Herceptin, in patients with operable, histologically node-positive breast cancer which overexpresses the HER2 protein; and 2)to determine whether, in this patient population, four cycles of AC followed by four cycles of Taxol and weekly Herceptin for one year is more effective in prolonging survival than four cycles of AC followed by four cycles of Taxol